digoxin (lanoxin) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Digoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX) in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.   NCATS

Chemistry

  • SMILES: C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C
  • InChIKey: LTMHDMANZUZIPE-PUGKRICDSA-N
  • Mol. Mass: 780.9385
  • ALogP: 2.22
  • ChEMBL Molecules:
    digoxin  
    acetyldigoxin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.0141 - $11.7070

United States

$0.1420 - $129.4190
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

12beta-hydroxydigitoxin | 12β-hydroxydigitoxin | 4-[(3s,5r,8r,9s,10s,12r,13s,14s)-3-[(2s,4s,5r,6r)-5-[(2s,4s,5r,6r)-5-[(2s,4s,5r,6r)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5h-furan-2-one | 6-dig | acetyldigoxin | beta acetyldigoxin | beta-acetyldigoxin | cardiogoxin | digamex | digazolan | digossina | digoxin | digoxina | digoxine | digoxin pediatric | digoxinum | lanadicor | lanoxicaps | lanoxin | lanoxin-125 | lanoxin pediatric | lanoxin-pg | novodigal | vanoxin

Organizations (186)

Research & Development (168)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (73)

Approved Indications (2)


 

Atrial Fibrillation

Heart Failure

Experimental Indications - Clinical Trial Phases 1-4 (73)


 

Abortion, Induced (Phase 4)

Alcohol-Induced Disorders (Phase 2)

Alzheimer Disease (Phase 1)

Angioedemas, Hereditary (Phase 1)

Arrhythmias, Cardiac (Phase 3)

Arthritis, Rheumatoid (Phase 2)

Atrial Fibrillation ()

Atrial Function, Left (Phase 3)

Bacterial Infections (Phase 1)

Body Weight (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cardiomyopathy, Dilated (Phase 4)

Cardiovascular Diseases (Phase 3)

Chemical and Drug Induced Liver Injury (Phase 2)

Cytomegalovirus Infections (Phase 1)

Depression (Phase 1)

Depressive Disorder, Major (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1/Phase 2)

Drug Interactions (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Electrocardiography (Phase 3)

Endocrine System Diseases (Phase 2)

Epilepsy (Phase 1)

Erythrocytes, Abnormal (Phase 1)

Essential Hypertension (Phase 1)

Fetal Development (Phase 3)

Glucose Metabolism Disorders (Phase 2)

Head and Neck Neoplasms (Phase 1/Phase 2)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 3)

Heart Failure ()

Hepacivirus (Phase 1)

Hepatitis, Alcoholic (Phase 2)

Hepatitis B, Chronic (Phase 1)

HIV Infections (Phase 1)

Huntington Disease (Phase 1)

Hypertension (Phase 1)

Hypotension (Phase 3)

Inflammation (Phase 1)

Influenza, Human (Phase 1)

Insulin Resistance (Phase 2)

Ivabradine (Phase 3)

Keratosis, Actinic (Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Lung Diseases (Phase 1)

Lymphoid Tissue (Phase 2)

Melanoma (Phase 1)

Metabolic Diseases (Phase 2)

Mutation (Phase 1)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Orthostatic Intolerance (Early Phase 1)

Pain (Phase 1)

Pancreatic Neoplasms (Phase 2)

Pharmacokinetics (Phase 1)

Pharmacology (Phase 4)

Polycythemia (Phase 1)

Postural Orthostatic Tachycardia Syndrome (Early Phase 1)

Prostatic Neoplasms (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Sarcoma, Kaposi (Phase 2)

Substance-Related Disorders (Phase 1)

Tachycardia (Phase 3)

Tachycardia, Supraventricular (Phase 3)

Tuberculosis (Phase 1)

Tuberculosis, Multidrug-Resistant (Phase 1)

Tuberculosis, Pulmonary (Phase 1)

Volunteers (Phase 1)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 175
  • # of Trial Organizations: 168

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue